Delays in Intracerebral Hemorrhage Management Is Associated with Hematoma Expansion and Worse Outcomes: Changes in COVID-19 Era

Hyun Jin Han¹, Keun Young Park¹, Junhyung Kim², Woosung Lee³, Yun Ho Lee³, Chang Ki Jang⁴, Kwang-Chun Cho⁵, Sang Kyu Park⁵, Joonho Chung⁴, Young Sub Kwon³, Yong Bae Kim¹, Jae Whan Lee⁴, and So Yeon Kim⁵

¹Department of Neurosurgery, Severance Stroke Center, Severance Hospital, Yonsei University College of Medicine, Seoul; ²Department of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; ³Department of Neurosurgery, National Health Insurance Service Ilsan Hospital, Goyang; ⁴Department of Neurosurgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin; ⁵Department of Neurosurgery, International St. Mary’s Hospital, Catholic Kwandong University, Inchoen, Korea.

Purpose: The coronavirus disease 2019 (COVID-19) pandemic disrupted the emergency medical care system worldwide. We analyzed the changes in the management of intracerebral hemorrhage (ICH) and compared the pre-COVID-19 and COVID-19 eras.

Materials and Methods: From March to October of the COVID-19 era (2020), 83 consecutive patients with ICH were admitted to four comprehensive stroke centers. We retrospectively reviewed the data of patients and compared the treatment workflow metrics, treatment modalities, and clinical outcomes with the patients admitted during the same period of pre-COVID-19 era (2017–2019).

Results: Three hundred thirty-eight patients (83 in COVID-19 era and 255 in pre-COVID-19 era) were included in this study. Symptom onset/detection-to-door time [COVID-19; 56.0 min (34.0–106.0), pre-COVID-19; 40.0 min (27.0–98.0), \( p = 0.016 \)] and median door-to-intensive treatment time differed between the two groups [COVID-19; 349.0 min (177.0–560.0), pre-COVID-19; 184.0 min (134.0–271.0), \( p < 0.001 \)]. Hematoma expansion was detected more significantly in the COVID-19 era (39.8% vs. 22.1%, \( p = 0.002 \)). At 3-month follow-up, clinical outcomes of patients were worse in the COVID-19 era (Good modified Rankin Scale; 33.7% in COVID-19, 46.7% in pre-COVID-19, \( p = 0.039 \)).

Conclusion: During the COVID-19 era, delays in management of ICH was associated with hematoma expansion and worse outcomes.

Key Words: COVID-19, hemorrhage, incidence, stroke

INTRODUCTION

On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak a pandemic.¹ Many countries have tried to prevent the spread of COVID-19 by avoiding physical contact and improving personal hygiene in public life. In medical institutions, further restrictions have also been implemented under limited resources, and most medical resources have been used to cope with the COVID-19 pandemic. However, these efforts to prevent the spread of COVID-19 caused significant changes in the diagnosis and treatment processes of acute illness in the clinical field.²,³ Similarly, changes in the management of acute stroke care have also been reported in recent studies.⁴,⁵ However, these previous studies mainly focused on patients with acute ischemic stroke, not with acute hemorrhagic stroke.

© Copyright: Yonsei University College of Medicine 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

www.eymj.org
Spontaneous intracerebral hemorrhage (ICH) is a disease that accounts for up to 24% of hemorrhagic strokes and can be fatal with a 1-month mortality rate of up to 40%. High blood pressure and hematoma expansion are associated with poor functional outcomes or death after ICH. Therefore, patients with ICH require acute intensive management regarding blood pressure and intracranial pressure to reduce the risk of a fatal outcome. As a result, management in the intensive care unit (ICU) is essential for patients with ICH. However, a significant amount of medical resources is being consumed for the treatment of COVID-19, and little is known about the effect of this uneven distribution of resources on the acute management of ICH in the COVID-19 era.

Globally, studies are being initiated in patients with acute hemorrhagic stroke. However, these studies have only shown the incidence of hemorrhagic stroke in patients with COVID-19, and information pertaining to the impact of COVID-19 on the treatment of hemorrhagic stroke is still lacking.

Therefore, in the present study, we aimed to evaluate and compare the changes in the management of ICH between the pre-COVID-19 and COVID-19 eras.

**MATERIALS AND METHODS**

**Study design**

Institutional Review Board of Catholic Kwandong University (JS20EIME0065), Yonsei University Severance Hospital (4-2020-0577), Yonsei University Gangnam Severance Hospital (3-2020-0364) and the National Health Insurance Service (NHIS) (NHIMC 2021-07-039) approved this study. Also, the need to obtain patient informed consent was waived because of the retrospective study design. The study was performed under the guidelines outlined by the Declaration of Helsinki, and the manuscript followed the STROBE checklist.

**Patient population**

In this study, we defined the COVID-19 era as the period from March to October 2020, whereas the same period during the preceding three years i.e., March to October in 2017, 2018, and 2019 is defined as the pre-COVID-19 era. Overall, during the pre-COVID-19 and COVID-19 eras, a total of 560 patients were admitted with ICH to four comprehensive stroke centers. Among them, the following patients were excluded: 1) patients aged <18 years; 2) patients who were transferred from another hospital under previous intensive treatment; 3) those whose diagnosis was delayed by >6 hours after symptom onset; and 4) those with ICH due to aneurysm, arteriovenous malformation, or any vasculopathy. Finally, 338 patients (83 in the COVID-19 era and 255 in the pre-COVID-19 era) were included in this study.

All clinical and radiological data were obtained from electronic medical records and retrospectively reviewed and compared between the COVID-19 and pre-COVID-19 era.

**COVID-19 prevention guidelines**

On February 20, 2020, the Korea Centers for Disease Control and Prevention issued guidelines on screening for COVID-19 in emergency departments. According to the guidelines, a screening test of COVID-19 should be performed through a separate triage space for suspected patients with 1) pneumonia of unknown cause, 2) respiratory symptoms with a recent visit to a contaminated area within 14 days, or 3) respiratory symptoms with recent contact with a COVID-19 (+) patient within 14 days.

Additionally, basic precautionary measures should be implemented for all suspected patients, and contact and airborne precautions are to be applied depending on the situation (Fig. 1). COVID-19 (+) or suspected patients should be isolated and treated in a negative pressure room within a triage space in the emergency department. Only authorized healthcare personnel can contact the COVID-19 (+) or suspected patient while wearing personal protective equipment. If the patient requires surgical or interventional treatment, intubation should be performed only by authorized healthcare personnel in a negative-pressure room or in an air-exchange room at least 12 times per hour.

**Fig. 1. Korea Centers for Disease Control and Prevention guidelines for COVID-19 in medical institutions. COVID-19, coronavirus disease 2019.**
hour. As the number of healthcare personnel participating in the surgery or intervention is limited, all of them should wear personal protective equipment (full-body protective clothing, N95 masks, gloves, hats, goggles, or face shields); powered air-purifying respirators may be used, if possible. Then, the COVID-19 (+) or suspected patient should be treated in a specialized ward or ICU for COVID-19. After the confirmation of COVID-19 (-), all processes should be conducted in the usual manner. The four comprehensive stroke centers participating in this study followed all of the aforementioned guidelines.

Image study analysis
Based on the protocol of the institution, follow-up computed tomography (CT) images were obtained after admission to evaluate hematoma expansion. Most patients had a follow-up CT scan performed on the following day, 12–24 hours after symptom onset/detection, unless their neurologic status worsened or they were suspected to have experienced a change in their intracranial pressure. ICH volume was defined using the ABC/2 formula, and assessed at the time of each CT scan. Hematoma expansion was determined as an increase in the initial volume by >33% or an increase of hematoma volume by >6 mL in the follow-up CT scan, as reported in previous studies. The image acquisition, measurement, and analysis were conducted by three independent investigators (H.J.H, Y.H.L, and SYK). In case of disagreement, another neurosurgeon (K.Y.P) reviewed the data, and four investigators decided on the final results with consensus.

Outcome measurements
The following workflow metrics (measured in minutes) of each patient were evaluated: 1) symptom onset/detection-to-door time; 2) door-to-imaging time; 3) door-to-intensive treatment time; and 4) overall symptom onset/detection-to-intensive treatment time. Intensive treatment was defined as the best medical treatment for managing blood pressure and intracranial pressure, correction of coagulopathy, or reversal of anticoagulants in the neuro-critical care unit. Surgical treatment was also divided into catheter surgery and open surgery. At the 90-day follow-up, functional outcome was assessed by experienced neurosurgeons or rehabilitation medicine physicians using the modified Rankin Scale (mRS). An unfavorable outcome was defined as mRS score of 3 or more. All variables were compared between the COVID-19 and pre-COVID-19 groups.

Statistical analyses
For comparison between the two groups, univariate analysis was performed using chi-squared test, Fisher’s exact test, Mann-Whitney U test, and standard t-tests. Multivariable analysis was performed on variables with a p<0.10 on univariate analysis. Binary logistic regression analysis was used to perform multivariable analysis for hematoma expansion and 90-day functional outcome. Significance was defined as p<0.05. Statistical analyses were performed using IBM SPSS Statistics version 25.0 for Windows (IBM Corp., Armonk, NY, USA).

RESULTS
During the COVID-19 era, 83 patients (average age of 63.4 years) were treated for ICH in four comprehensive stroke centers. In the same period during the pre-COVID-19 era, 255 patients (85 patients/year, average age of 60.7 years) were treated for ICH in the same centers. There were no significant differences in baseline characteristics, medical history, or initial GCS between the two groups (Table 1).

Regarding workflow metrics, symptom onset/detection-to-door time was significantly different between the two groups [COVID-19; 56.0 min (34.0–106.0), pre-COVID-19; 40.0 min (27.0–98.0), p=0.016]. Door-to-imaging time did not significantly differ between the two groups, but showed a tendency to delay in the COVID-19 group [COVID-19; 24.0 min (15.0–38.0), pre-COVID-19; 20.0 min (13.0–32.0), p=0.082]. Door-to-intensive treatment time [COVID-19; 349.0 min (177.0–560.0), pre-COVID-19; 184.0 min (134.0–271.0), p<0.001] showed a significant delay during the COVID-19 era. Finally, the overall symptom onset/detection-to-intensive treatment time was significantly delayed in the COVID-19 group [COVID-19; 430.0 min (248.0–640.0), pre-COVID-19; 255.0 min (189.0–375.0), p<0.001] (Table 2 and Fig 2).

Table 3 shows a comparison of the characteristics of the hematoma expansion (+) and (-) groups. Previous cerebrovascular accident (CVA) history (p<0.001), antithrombotic usage (p<0.001), initial GCS (p=0.011), and delayed door-to-intensive treatment time (p=0.046) were risk factors related to hematoma expansion. In the multivariable logistic regression analysis, previous cerebrovascular accident (CVA) history [odds ratio (OR): 2.818, 95% confidence interval (CI): 1.438–5.522]; low initial GCS (OR: 1.108, 95% CI: 1.037–1.184); and delayed door-to-intensive treatment time (OR: 0.998, 95% CI: 0.997–1.000) were significant predictors of hematoma expansion.

Table 1. Baseline Characteristics and Risk Factors of Intracerebral Hemorrhage Patients

| Variable | COVID-19 (n=83) | Pre-COVID-19 (n=255) | p value |
|----------|-----------------|----------------------|---------|
| Age, yr  | 63.4 (14.4)     | 60.7 (16.4)          | 0.185   |
| Sex, male| 43 (51.8)       | 148 (58.0)           | 0.320   |
| Medical history |          |                      |         |
| Hypertension | 48 (57.8)     | 149 (58.4)           | 0.923   |
| Current smokers | 32 (38.6)   | 90 (35.3)            | 0.591   |
| Antithrombotic usage | 27 (32.5)   | 66 (25.9)            | 0.239   |
| Previous CVA | 20 (24.1)     | 54 (21.2)            | 0.576   |
| Initial GCS | 11.6 (4.00)   | 10.9 (4.30)          | 0.175   |

COVID-19, coronavirus disease 2019; SD, standard deviation; CVA, cerebrovascular accident; GCS, Glasgow Coma Scale.
Data are presented as mean (SD) or n (%).
Intracerebral Hemorrhage and COVID-19

were significant independent risk factors for hematoma expansion (Table 4).

At the 90-day follow-up visit (available in all patients), patients in the COVID-19 group had a worse functional outcome compared to those in the pre-COVID-19 group (Table 5 and Fig.

### Table 2. Workflow Metrics, Treatment Details, and Clinical Outcomes

|               | COVID-19 (n=83) | Pre-COVID-19 (n=255) | p value |
|---------------|-----------------|----------------------|---------|
| Symptom onset/detection-to-door time | 56.0 (34.0–106.0) | 40.0 (27.0–98.0) | 0.016* |
| Door-to-imaging time | 24.0 (15.0–38.0) | 20.0 (13.0–32.0) | 0.082 |
| Door-to-intensive treatment time | 349.0 (177.0–560.0) | 184.0 (134.0–271.0) | <0.001* |
| Symptom onset/detection-to-intensive treatment time | 430.0 (248.0–640.0) | 255.0 (189.0–375.0) | <0.001* |
| Hematoma expansion | 33 (39.8) | 47 (22.1) | 0.002* |
| Treatment modality | 0.180 |
| Medical intensive care | 56 (67.5) | 151 (59.2) |
| Surgical treatment | 27 (32.5) | 104 (40.8) |
| Surgical treatment | 0.170 |
| Catheter surgery | 18 (66.7) | 54 (51.9) |
| Open surgery | 9 (33.3) | 50 (48.1) |
| 90-day functional outcome | 0.039* |
| Unfavorable (mRS ≥3) | 55 (66.3) | 136 (53.3) |

COVID-19, coronavirus disease 2019; IQR, interquartile range; mRS, modified Rankin Scale. Workflow metrics measured in minutes. Data are presented as median (IQR) or n (%).

*Statistically significant. †296 patients could be included for hematoma expansion analysis.

### Table 3. Comparison between Hematoma Expansion (+) vs. (-) Sub-groups

|               | Hematoma expansion (+) (n=80) | Hematoma expansion (-) (n=216) | p value |
|---------------|--------------------------------|--------------------------------|---------|
| Age, yr | 63.1 (14.4) | 61.5 (16.3) | 0.420 |
| Sex, male | 50 (62.5) | 118 (54.6) | 0.225 |
| Medical history |                                |                                |         |
| Hypertension | 50 (62.5) | 125 (57.9) | 0.472 |
| Current smokers | 36 (45.0) | 77 (35.6) | 0.141 |
| Antithrombotic usage | 37 (46.3) | 48 (22.2) | <0.001* |
| Previous CVA | 34 (42.5) | 37 (17.1) | <0.001* |
| Initial GCS | 10.0 (4.23) | 11.4 (4.22) | 0.011* |
| Symptom onset/detection-to-door time, median (IQR) | 41.5 (28.3–83.3) | 51.0 (30.0–118.5) | 0.152 |
| Door-to-imaging time, median (IQR) | 20.0 (13.0–32.0) | 20.0 (13.0–31.0) | 0.478 |
| Door-to-intensive treatment time, median (IQR) | 219.0 (151.0–395.0) | 194.0 (134.0–295.0) | 0.045* |
| 90-day functional outcome | 0.003* |
| Unfavorable (mRS ≥3) | 57 (71.3) | 113 (52.3) |

SD, standard deviation; CVA, cerebrovascular accident; GCS, Glasgow Coma scale; IQR, interquartile range; mRS, modified Rankin Scale. Workflow metrics measured in minutes. Data are presented as mean (SD) or n (%).

*Statistically significant.

### Table 4. Multivariable Analysis of Hematoma Expansion

|               | Multivariable analysis |
|---------------|-----------------------|
| Antithrombotic usage | 1.780 (0.942–3.363) |
| Previous CVA history | 2.818 (1.438–5.522) |
| Initial GCS | 1.108 (1.037–1.184) |
| Symptom onset/detection-to-door time | 1.001 (0.997–1.004) |
| Door-to-intensive treatment time | 0.998 (0.997–1.000) |

OR, odds ratio; CI, confidence interval; CVA, cerebrovascular accident; GCS, Glasgow Coma Scale.

3). In the analysis restricted to patients who were independent, 55 patients (66.3%) in the COVID-19 group and 136 patients (53.3%) in the pre-COVID-19 group had an unfavorable mRS score (≥3) (p=0.039). In the multivariable logistic regression analysis, COVID-19 era (OR: 3.122, 95% CI: 1.571–6.203); low initial GCS (OR: 0.663, 95% CI: 0.593–0.741); hematoma expansion (OR: 2.003, 95% CI: 1.004–3.997); medical intensive care (OR: 4.057, 95% CI: 1.984–8.298); and older age (OR: 1.038, 95% CI: 1.017–1.060) were independent predictors of an unfavorable functional outcome at 90 days (Table 5).

### DISCUSSION

During the last year of the COVID-19 pandemic, 2020, governments and medical institutions have done their best to pre-
transport. Nguyen, et al. suggested that thrombectomy should be performed with the minimum number of medical personnel under protection, using communication equipment such as telecommunication and environmental management. Lastly, a recent study has shown that there was no delay in acute stroke management, including in-hospital workflow metrics. Unfortunately, such efforts were mainly limited to acute ischemic stroke management, as only few hospitals have protocols specific to the management of ICH comparing with acute ischemic stroke.

Several studies also reported that the COVID-19 pandemic decreased the number of hospital admissions and reperfusion therapy. In a study by Rudilosso, et al. in March 2020, the number of stroke codes in Catalonia declined by 23% compared to that of March 2019 \( (p=0.009) \). In another study by Zhao et al., a significant decrease in reperfusion therapy in China was reported \( (p<0.0001) \), and it was suggested that the potential reason for the decreased number of stroke patients was a “fear of contracting COVID-19 in hospital.” On the other hand, in the present study, the number of hospital admissions during the COVID-19 era (2020) was not different compared to the same period during the pre-COVID-19 era (2017–2019). It remains uncertain as to why the number of patients with ICH did not decrease during the COVID-19 era, unlike of those with acute ischemic stroke or coronary disease. In our theory, it is because patients with ICH present with more severe neurological status, and many patients or their legal representatives might have a “fear of fatality due to hemorrhagic stroke” rather than a “fear of contracting COVID-19 in hospital.” This result was also supported by a study by Diegoli, et al., in which the number of admissions for ischemic stroke was significantly decreased in Joinville, but that for hemorrhagic stroke, including intraparenchymal and subarachnoid hemorrhage, was not different between the pre-COVID-19 and COVID-19 eras.

In the present study, the ICH patient group of the COVID-19 era showed a significant time delay in both symptom onset-to-intensive treatment time and door-to-intensive care time. In subgroup analysis, the door-to-intensive treatment time was markedly increased in patients whose history was unclear or those who were suspected of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to the patients not suspected to be infected (427.3 minutes and 207.8 minutes, respectively). In the emergency room, the waiting time for the SARS-CoV-2 test result or for available ICU beds among those categorized as possible COVID-19 patients might be increased. Generally, if the operation of an emergency department focuses on the prevention of SARS-CoV-2 transmission, this affects the treatment process of many acute illnesses, including the workflow of ICH management. Since there was no secured transport pathway from the emergency room to the operating room and from the operating room to the ICU, delays in patient transfer were unavoidable. The changes introduced in the COVID-19 era led to delays, which resulted in hematoma expansion.

Hematoma expansion, one of the major concerns of acute ICH management, occurred more frequently during the COVID-19 era, which led to a poorer clinical outcome than in the pre-COVID-19 era. In the literature, hematoma expansion is known to occur in up to 30% of patients, and several studies have suggested that intensive treatment, including blood pressure control, reversal of coagulopathy, and surgical treat-

---

**Fig. 3.** Comparison of the 90-day functional outcomes between COVID-19 and pre-COVID-19 eras. COVID-19, coronavirus disease 2019.

**Table 5.** Univariate and Multivariable Regression Analyses of Unfavorable Functional Outcomes at 90 Days

|                      | Univariate analysis | Multivariable analysis |
|----------------------|---------------------|------------------------|
|                      | OR      | 95% CI   | OR      | 95% CI   |
| COVID-19 era         | 1.719   | 1.025–2.883 | 3.122   | 1.571–6.203 |
| GCS                  | 0.635   | 0.573–0.703 | 0.663   | 0.593–0.741 |
| Hematoma expansion (+)| 3.641   | 2.142–6.191 | 2.003   | 1.004–3.997 |
| Medical intensive care| 8.811   | 5.072–15.305 | 4.057   | 1.984–8.298 |
| Age                  | 1.018   | 1.004–1.032 | 1.038   | 1.017–1.060 |

OR, odds ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; GCS, Glasgow Coma Scale.
In terms of clinical outcome, the functional outcome at 90 days of ICH patients was worse in the COVID-19 era than in the pre-COVID-19 era. In the multivariable analysis, an unfavorable 90-day functional outcome was associated with low GCS, medical intensive care only, and advanced age. The association between advanced age and poor functional outcome at 90 days might be due to some older patients with large hematomas refusing surgical treatment. More importantly, hematoma expansion and the COVID-19 era were associated with unfavorable functional outcomes at 90 days, and delay of door-to-intensive care time was a significant risk factor for hematoma expansion.

In the COVID-19 era, delay in the emergency room and interference of ICH workflow might lead to hematoma expansion; as a result, the overall changes might be associated with unfavorable clinical outcomes.

To our knowledge, the present study is the first regarding delays in the management of patients with ICH in the COVID-19 era. However, our study had several limitations. First, due to the limitations inherent in the retrospective design with short-term follow-up, a selection bias was inevitable regarding the demographics and percentages observed. Second, the population of this study was limited to the specific area of South Korea. Therefore, our results cannot be generalized and directly applied to other areas or countries around the world. Also, the ICH and hematoma expansion volume could not be measured, and accurate records of the CT follow-up time could not be obtained. Nevertheless, to the best of our knowledge, this study is the first and the largest study on ICH management in the COVID-19 pandemic, and could be helpful in evaluating stroke management in the COVID-19 era in future studies.

These results illustrate the adverse effect of non-standardized ICH management in the COVID-19 era on functional outcomes as a consequence of changes in the workflow metrics and increased hematoma expansion. During the COVID-19 era, ICH management was delayed, and hematoma expansion occurred more frequently. Furthermore, clinical outcomes were significantly different from those of the pre-COVID-19 era. Considering the results of this study, the treatment process for ICH patients in the COVID-19 era should be reviewed, and developing a special intensive care protocol for ICH patients should be considered.

ACKNOWLEDGEMENTS

We would like to thank the Biostatistics Collaboration Unit of Yonsei University College of Medicine for statistical consultation.

AUTHOR CONTRIBUTIONS

Conceptualization: Hyun Jin Han, Keun Young Park, and So Yeon Kim. Data curation: Junhyung Kim, Woosung Lee, and Yun Ho Lee. Formal analysis: Hyun Jin Han. Investigation: Hyun Jin Han. Methodology: Keun Young Park, Junhyung Kim, Woosung Lee, Yun Ho Lee, and So Yeon Kim. Project administration: Keun Young Park, Kwang-Chun Cho, Chang Ki Jang, Sang Kyu Park, Joonho Chung, Young Sub Kwon, Yong Bae Kim, Jae Whan Lee, and So Yeon Kim. Resources: Keun Young Park, Junhyung Kim, Woosung Lee, Kwang-Chun Cho, Yun Ho Lee, Chang Ki Jang, Sang Kyu Park, Joonho Chung, Young Sub Kwon, Yong Bae Kim, Jae Whan Lee, and So Yeon Kim. Software: Hyun Jin Han. Supervision: Keun Young Park and So Yeon Kim. Validation: Junhyung Kim, Woosung Lee, Yun Ho Lee, and So Yeon Kim. Visualization: Hyun Jin Han. Writing—original draft: Hyun Jin Han. Writing—review & editing: So Yeon Kim. Approval of final manuscript: all authors.

ORCID iDs

Hyun Jin Han https://orcid.org/0000-0002-4111-4819
Keun Young Park https://orcid.org/0000-0002-3254-4577
Junhyung Kim https://orcid.org/0000-0002-8908-978X
Woosung Lee https://orcid.org/0000-0002-4981-1088
Yun Ho Lee https://orcid.org/0000-0001-8156-5414
Chang Ki Jang https://orcid.org/0000-0001-8715-8844
Kwang-Chun Cho https://orcid.org/0000-0002-0621-9283
Sang Kyu Park https://orcid.org/0000-0001-9231-0716
Joonho Chung https://orcid.org/0000-0003-2745-446X
Young Sub Kwon https://orcid.org/0000-0002-2996-2145
Yong Bae Kim https://orcid.org/0000-0003-2262-7157
Jae Whan Lee https://orcid.org/0000-0002-9051-5651
So Yeon Kim https://orcid.org/0000-0002-4339-069X

REFERENCES

1. Mahase E. COVID-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ 2020;369:m1036.
2. Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 pandemic. JAMA 2020;323;2005-6.
3. Tam CF, Cheung KS, Lam S, Wong A, Yung A, Sze M, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes 2020;13:e006631.
4. Rudilosso S, Laredo C, Vera V, Vargas M, Renú A, Llull L, et al. Acute stroke care is at risk in the era of COVID-19: experience at a comprehensive stroke center in Barcelona. Stroke 2020;51:1991-5.
5. Teo KC, Leung WCY, Wong YK, Liu RKC, Chan AHY, Choi OMY, et al. Delays in stroke onset to hospital arrival time during COVID-19. Stroke 2020;51:2228-31.
6. Hong KS, Bang OY, Kang DW, Yu KH, Bae HJ, Lee JS, et al. Stroke statistics in Korea: part I. Epidemiology and risk factors: a report from the Korean Stroke Society and Clinical Research Center for Stroke. J Stroke 2013;15:2-20.
7. Qureshi AI, Mendelow AD, Hanley DE. Intracerebral haemorrhage.
Lancet 2009;373:1632-44.
8. Toyoda K. Epidemiology and registry studies of stroke in Japan. J Stroke 2013;15:21-6.
9. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167-76.
10. Anderson CS, Heelley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355-65.
11. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med 2001;29:635-40.
12. Naval NS, Carhuapoma JR. Impact of pattern of admission on ICH outcomes. Neurocrit Care 2010;12:149-54.
13. Vanlals PN, Schulz L, Conti M, Spanaki M, Genarrelli T, Hacein-Bey L. The impact of a neuro-intensive unit on patients with stroke admitted to a neurosciences intensive care unit. Neurocrit Care 2008;9:293-9.
14. Brouwers HB, Chang Y, Falcone GJ, Cai X, Ayres AM, Battey TW, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 2014;71:158-64.
15. Pandey AS, Daou BI, Tsai JP, Zaidi SF, Salahuddin H, Gemmete JJ, et al. Letter: COVID-19 pandemic—the bystander effect on stroke care in Michigan. Neurosurgery 2020;87:E397-9.
16. Estevez-Ordonez D, Laskay NMB, Chagoya G, Alam Y, Artchley TJ, Elsayed GA, et al. Perioperative and critical care management of a patient with severe acute respiratory syndrome corona virus 2 infection and aneurysmal subarachnoid hemorrhage. Neurosurgery 2020;87:E243-4.
17. Korea Disease Control and Prevention Agency. Korea Centers for Disease Control and Prevention guidelines for COVID-19 in medical institutions [accessed on 2020 February 28]. Available at: http://kdca.go.kr/board/board.es?mid=a20507020000&bid=0019.
18. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1-5.
19. Brouwers HB, Falcone GJ, McNamara KA, Ayres AM, Oleinik A, Schwab K, et al. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage. Neurocrit Care 2012;17:421-8.
20. Goldstein JD, Fazeni LE, Snider R, Schwab K, Greenberg SM, Smith EE, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007;68:889-94.
21. Li Q, Liu QJ, Yang WS, Wang XC, Zhao LB, Xiong X, et al. Island sign: an imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage. Stroke 2017;48:3019-25.
22. Nguyen TN, Abdalkader M, Jovin TG, Nogueira RG, Jadhav AP, Haussen DC, et al. Mechanical thrombectomy in the era of the COVID-19 pandemic: emergency preparedness for neuroscience teams: a guidance statement from the Society of Vascular and Interventional Neurology. Stroke 2020;51:1896-901.
23. Smith MS, Bonorno J, Knight WA 4th, Prestigiacomo CJ, Richards CT, Ramser E, et al. Endovascular therapy for patients with acute ischemic stroke during the COVID-19 pandemic: a proposed algorithm. Stroke 2020;51:1902-9.
24. Kurz MW, Orsel JM, Daehli Kurz K, Goyal M. Improving stroke care in times of the COVID-19 pandemic through simulation: practice your protocols! Stroke 2020;51:2273-5.
25. Cooper D, Jauch E, Flaherty ML. Critical pathways for the management of stroke and intracerebral hemorrhage: a survey of US hospitals. Crit Pathw Cardiol 2007;6:18-23.
26. Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R. Impact of the COVID-19 epidemic on stroke care and potential solutions. Stroke 2020;51:1996-2001.
27. Kerleroux B, Fabacher T, Bricout N, Moïse M, Testud B, Vingadasalom S, et al. Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: decreased activity, and increased care delays. Stroke 2020;51:2012-7.
28. Diegoli H, Magalhães PSC, Martins SCO, Moro CHC, França PHC, Safanelli J, et al. Decrease in hospital admissions for transient ischemic attack, mild, and moderate stroke during the COVID-19 era. Stroke 2020;51:2315-21.
29. Butcher KS, Jeerksthiil T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke 2013;44:620-6.
30. Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke 2013;44:1846-51.
31. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yunidt K, Aiyagari V, et al. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001;21:804-10.
32. Huhtakangas J, Tieti S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011;42:2431-5.